PHE’s Baumgardner to Present on CAR-T Therapy Outcomes at ASH

Senior Research Economist James Baumgardner will be presenting “CAR-T Therapy Displays Favorable Gains in Health Outcomes and Competitive Cost-Effectiveness When Compared with Past Innovative Cancer Treatments” at the American Society of Hematology (ASH) 60thAnnual Meeting and Exposition, taking place from December 1-4 in San Diego, CA.

In the presentation, Dr. Baumgardner will share evidence on the past 10 to 20 years of anti-cancer innovation in terms of outcomes — measured by incremental quality-adjusted life years (QALYs) -– and in terms of cost effectiveness -– measured by incremental cost per QALY.  The presentation will demonstrate how novel CAR-T therapy appears to break from previous trends.

For more information on ASH, or Dr. Baumgardner’s presentation, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.